Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 9/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14035606 | 0.88 | GAA (0.46) | GAAALDH1A1LMNACYP2C9CYP1A2 | |
| SCHEMBL11696381 | 0.80 | FAAH (0.55) | GAAALDH1A1LMNACYP2C9CYP1A2 | |
| SCHEMBL14573137 | 0.80 | FAAH (0.55) | GAAALDH1A1LMNACYP2C9CYP1A2 | |
| SCHEMBL9946939 | 0.80 | FAAH (0.55) | GAAALDH1A1LMNACYP2C9CYP1A2 | |
| SCHEMBL4299698 | 0.79 | MAOB (0.67) | GAAALDH1A1MAOBMAPT | |
| SCHEMBL3824529 | 0.79 | MAOB (0.67) | GAAALDH1A1MAOBMAPT | |
| SCHEMBL13971346 | 0.78 | HPGD (0.44) | GAAALDH1A1LMNACYP2C9CYP1A2 | |
| SCHEMBL14206850 | 0.76 | GAA (0.52) | GAAALDH1A1LMNACYP2C9CYP1A2 | |
| SCHEMBL11406654 | 0.76 | GRIN2D (0.53) | GAAALDH1A1MAOBMAPTTSHR | |
| SCHEMBL11406653 | 0.76 | GRIN2D (0.53) | GAAALDH1A1MAOBMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264402-A1 | NOVEL DIPHENYLAZETIDINONE SUBSTITUTED BY PIPERAZINE-1-SULFONIC ACID AND HAVING IMPROVED PHARMACOLOGICAL PROPERTIES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
| WO-2008052658-A1 | NOVEL DIPHENYLAZETIDINONE SUBSTITUTED BY PIPERAZINE-1-SULFONIC ACID HAVING IMPROVED PHARMACOLOGICAL PROPERTIES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264402-A1 | NOVEL DIPHENYLAZETIDINONE SUBSTITUTED BY PIPERAZINE-1-SULFONIC ACID AND HAVING IMPROVED PHARMACOLOGICAL PROPERTIES | DPP7, SCN5A, DCTN1 | GAA 1143/4885ALDH1A1 24/4885LMNA 3943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.